, as BCEC series coordinator. This meeting was the second edition of the BCEC series, which was launched by 5 leading Barcelonan institutes to bring together leading investigators in the fields of epigenetics and chromatin research. The topics discussed during the meeting included the current challenges, opportunities, and perspectives surrounding the study of histone modifications (focusing in acetylation), chromatin structure and gene expression, and the involvement of histone acetylation in physiology and diseases, such as cancer or neurological diseases.
knockdown reduces cell proliferation and induces cell cycle arrest at G1, providing a potential target for new MLL inhibitors.
Jerry Workman (Stowers Institute for Medical Research, Kansas City, USA) talked about histone acetyltransferase complexes. The general control of amino acid synthesis 5 (GCN5) subunit of Spt-Ada-Gcn5 acetyltransferase (SAGA) chromatin-modifying complex is responsible for sucrose non-fermenting (Snf2) acetylation. Snf2 acetylation, within switch of the mating type (Swi/Snf) chromatin remodeling complex, reduces the binding of this complex to acetylated nucleosomes and affects Swi/Snf complex genome wide occupancy. Besides, HATs regulate the genomic dynamics of chromatin remodelers through acetylation of histones, acetylation of remodelers, and a possible competition between remodelers. Dr. Workman focused the last part of his talk on the role of enoki mushroom (Enok), the fly homolog of the human monocytic leukemia zinc finger protein (MOZ), YBF2, something about silencing-2 (SAS-2), TAT-interactive protein 60 (Tip60) (MYST3) acetyltransferase. Enok is expressed at high levels in embryos and localized to spire (spir) and mael (maelstrom) in oocytes. Moreover, Enok acetylates H3K23 in flies, playing a crucial role in oogenesis.
Colyn Crane-Robinson (University of Portsmouth, Portsmouth, UK) began his lecture by discussing his laboratory's initial undertaking: generating specific antibodies against acetylated histone residues. After performing ChIP experiments using anti-AcH4 and anti-AcH2A.Z antibodies, Dr. Crane-Robinson's team could confirm that both histone modifications frequently co-habit the same nucleosomes. Moreover, by using ChIP-Seq experiments they were able to show that AcH2A.Z is present at both active and poised (bivalent) transcription start signal (TSS), at enhancers and at insulators. He proposed the concept of H2A.Z, typically acetylated, as a general facilitator of nucleosome remodeling that allows access to chromatin by a wide variety of activating and repressing complexes.
Lorraine Pillus (University of California San Diego, California, USA) described some aspects of MYST family proteins. KAT5 lysine acetyltransferase 5 (Tip60) is the human homolog of (essential SAS family (Esa1) acetyltransferase in yeast. Both enzymes are essential for cell viability, and genomic aberration of Tip60 is found in human carcinomas. Dr. Pillus presented that it is possible to rescue the phenotype of of esa1Δ cells by deletion of SDS3, which encodes a non-catalytic subunit of the reduced potassium depending 3 large (Rpd3L) deacetylase complex. Furthermore, she reported that a new mark, H2A-pY57, is critical in casein kinase 2 (CK2) mediated transcriptional elongation which helps explain why earlier studies found the H2A-Y57A mutation to be lethal. The H2A-Y57F mutants affect histone modifications involved in transcriptional regulation.
Jean-Marc Victor (University of Pierre & Marie Curie, Paris, France) explained a physical view of the correlation between transcriptional activity and histone modifications through a mechanistic and spatial structure explanation based on allostery. The allostery in DNA and protein interactions can play an important role in gene regulation. He showed how the chromatin fiber provides a proof of principle for this model. The anchoring mode of DNA is controlled by the acetylation of H3, determining a clamped mode when the H3 tail is de-acetylated or, in contrast, a free hinged mode when it is acetylated. The spatial structure of chromatin determined by the acetylation of the tails of histones also determines the affinity of proteins that bind to DNA, thus modulating gene expression.
Astrid Hagelkruys (Medical University of Vienna, Wien, Austria) examined the impact of HDAC1 and HDAC2 isoform-specific functions in the development of the brain and epidermis. The deletion of 3 of the 4 HDAC1/HDAC2 alleles has a different phenotype, depending on the remaining allele and the organ affected. In the brain, normal development occurs when only one allele of HDAC2 is remaining, whereas mice with a single allele of HDAC1 die shortly after birth. In contrast, mice with a single allele of HDAC1 in the epidermis have a normal epidermal development, but when only one allele of HDAC2 has expressed spontaneous papiloma formation and hyperkeratosis is observed. Protein kinase C (PRKCδ), which is a direct target of HDAC2, is an important regulator of cell death, cell cycle progression, and energy metabolism, and its inhibition rescues the differentiation phenotypes of HDAC1Δ/+n HDAC2 Δ/Δn neurospheres. PRKCδ promoter hyperacetylation by HDAC2 is responsible for this defective phenotype in the brain. James Davie (Manitoba Institute of Child Health, Manitoba, Canada) started his talk by describing a powerful chromatin fractionation method for chicken erythrocyte chromatin that had been previously elaborated in his lab. More recently, in combination with next generation DNA and RNA sequencing, it allowed them to define the organization of the chicken erythrocyte genome into chromosomal domains and obtain very useful information on the transcripts produced by these domains. In the second part of his talk, Dr. Davie focused on dynamic histone acetylation and RNA splicing. Histone deacetylases 1, 2) (HDAC1, HDAC2), and serine/arginine-rich splicing factor 1 (SRSF1) are involved in alternative splicing of the human myeloid cell leukemia sequence 1 (MCL1) gene. HDAC1/2 is recruited to MCL1 pre-mRNA by splicing factors and, together with KAT2B and other lysine acetyltransferases (KATs), catalyzes histone acetylation of MCL1 gene and directly regulates its splicing.
Rafael Casellas (NIAMS-NCI, National Institute of Health, Maryland, USA) discussed global chromatin acetylation and transcriptome amplification during lymphocyte activation. In G , there are mechanisms-such as limiting RNA Polymerase II recruitment and activity-that maintain the transcriptome at basal levels. Subunits of transcription factor II human (TFIIH) complex, including helicases involved in promoter melting, are generally downregulated in resting B cells (compared to activated B cells), and promoters are polymerase-loaded but unmelted. In contrast, when the immune response takes place, there is an increase in histone acetylation, promoter melting, and transcription across the genome in activated B cells, which correlates with the enhancement observed in the expression of TFIIH and Myc.
Maribel Parra (Cancer Epigenetics and Biology Program, PEBC-IDIBELL, Barcelona, Spain)
outlined the role of HDAC7 (histone deacetylase 7) in B lymphopoiesis. HDAC7 shows a lymphoidspecific expression pattern and is highly expressed in B lymphocytes, but not in myeloid cells such as macrophages. After reprogramming of pre-B cells intro macrophages by overexpression of C/EBPα, they found that HDAC7 shows a lymphoid-spedownregulated during the switch from pre-B cells to macrophages. However, reintroduction of HDAC7 causes de-repression of myeloid genes in pre-B cells and abolishes crucial functions of macrophages by interacting with the transcription factor myocyte enhancer factor 2C (MEF2C). In conclusion, Dr. Parra reported a novel role for HDAC7 as a lymphoidspecific transcriptional repressor of inappropriate genes in pre-B cells, which is required for their transdifferentiation to macrophages.
Histone Acetylation in Physiology and Disease
John Denu (University of Wisconsin, Wisconsin, USA) opened the session by talking about the relationship between deacetylation activity of sirtuins and metabolism. Dr. Denu's team has developed a quantitative mass spectrometry method to characterize the liver mitochondria acetyL-proteome during caloric restriction (in comparison to a control diet), in mice that lacked SIRT3 (versus wild type mice). Applying this technique, they observed that SIRT3 regulates mitochondrial metabolism, especially under caloric restriction by deacetylating proteins involved in several pathways of metabolism and mitochondrial maintenance. Furthermore, SIRT6 is a tumor suppressor that controls cancer metabolism. In fact, SIRT6 KO mice show metabolic and degenerative phenotypes, and die by 4 weeks of age. Free fatty acids are able to stimulate SIRT6 deacetylation activity, and myristic acid inhibits SIRT6 dependent de-myristoylation. These results suggest that fatty acids liberated from a fasting diet are able to condition SIRT6 activity, activating deacetylation and inhibiting de-myristoylation.
Eric Verdin (Gladstone Institutes, University of California, San Francisco, USA) discussed how natural metabolites can act as regulators of epigenetic enzymes, focusing on NAD+ and sirtuins. SIRT3 is exclusively located in mitochondria and regulates mitochondrial acetyl proteome. Dr. Verdin team compared the acetylation of lysines in liver mitochondria from SIRT3 KO mice vs. a wild type model using mass spectrometry, and found that 12% of the 16% acetylated lysines are regulated by SIRT3. In contrast, SIRT5 is a de-malonylase/de-succinylase in vitro and plays an important role in the regulation of fatty acid β-oxidation and plays an important role in the regulation of fatty acid e/de-succinylase 
by SIRT3 in response to fasting ; SIRT5 regulates succinylation of this ketogenic enzyme. In conclusion, SIRT3 is involved in the regulation of mitochondrial lysine acetylation, SIRT5 acts as a global regulator of lysine succinylation in mitochondria, and both sirtuins are involved in ketogeneis through regulation of HMGCS2. Program (PEBC-IDIBELL) , Barcelona, Spain) presented several unpublished results about a new role of SIRT6 in the stress response mediated by nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB). SIRT6 deacetylates H3K9 and regulates processes like telomere integrity and gene silencing, and it is the only sirtuin that causes an accelerated aging syndrome in KO mice. Most of this phenotype is due to hyperactivation of NF-kB pathway. Furthermore, SIRT6 interacts with the histone metyltransferase Suv39h1 set domain, but in contrast with SIRT1, loss of SIRT6 does not seem to alter Suv39h1 constitutive heterochromatin function. Interestingly, he described how SIRT6 overexpression induces mono-ubiquitination of 4 cysteines in the pre-set domain of suppressor of variegation 3-9 homolog 1 (Suv39h1), affecting cytoplasmatic signaling trafficking and avoiding the binding of this enzyme to chromatin. Mono-ubiquitination of Suv39h1 is related to proliferation, peaks at G1/S and G2/M, and is promoted by TNFα but not altered by other forms of stress. Dr. Vaquero's team proposed that S-phase kinaseassociated protein 2 (SKP2) is the enzyme responsible for the mono-ubiquitination of Suv39h1 in the context of NF-kB pathway, and SIRT6 interaction and deacetylation promotes increased levels and activity of SKP2.
Alejandro Vaquero (Cancer Epigenetics and Biology
Lourdes Serrano (Rutgers University, New Jersey University, USA) outlined the role of SIRT7 in the maintenance of genome integrity, presenting results from an unpublished project by her team. She described how SIRT7 KO mice exhibit increased perinatal lethality, reduced life span, and an accelerated aging phenotype. SIRT7 protects cells from endogenous and induced DNA damage, and participates in the DNA damage response by regulating tumor protein p53 binding protein 1 (53BP1) recruitment to DNA double-strand break (DSB) during non-homologous end-joining repair (NHEJ). Moreover, SIRT7 is recruited to DSB to promote H3K18 deacetylation. Their results demonstrate that SIRT7 modulates 53BP1 through regulation of H3K8Ac levels at DSB.
Ömer Copur (Max Planck Institute of Biochemistry, Martinsried, Germany) presented also unpublished data of an analysis of Drosophila H4K16ac function in vivo using a genetic system to generate embryos or cell clones consisting of histone point mutations (i.e., H4K16A or H4K16R). Histone acetyltransferase Mof (males absent on the first) is present in the male-specific lethal (MSL) complex, where H4K16 acetyl mark regulates hyperactivation of single male X chromosome as dosage compensation. It is also present in nonspecific lethal (NSL) complex, where it is involved in the expression of the housekeeping genes. In order to elucidate the function of H4K16ac, Dr. Copur's team generated H4K16 mutant flies. Both males and females lacking H4K16ac die during embryogenesis, meaning that this mark is essential for development. In contrast, Mof mutant females but not males were able to survive to adulthood. Furthermore, the analysis of Mof and H4K16A mutant cell clones in developing Drosophila showed that clone growth in males but not in females is impaired in the absence of functional Mof. However, H4K16ac null mutant male and female cells were able to differentiate into respective tissues. This indicates that lack of H4K16ac does not lead to perturbation of developmental pathways. Finally, lack of H4K16ac alters heterochromatin protein 1 (HP1) and the pattern of H3K9me2 distribution in males without affecting chromatin in female nuclei.
Li-Huei Tsai (Howard Hughes Medical Institute, Chevy Chase, USA) presented data about the epigenomics of Alzheimer Disease (AD). Given that a decrease in histone acetylation is characteristic of several neurodegeneration processes in mouse models, she described how HDAC inhibitor sodium butyrate treatment is able to reinstate learning and memory, following neurodegeneration. HDAC2 is a critical negative regulator of genes essential for synaptic plasticity, learning, and memory, and is induced by neurotoxicity and markedly upregulated in AD brain tissue. In fact, shRNA mediated HDAC2 knock down (K ) in the hippocampus is sufficient to restore synaptic density and gene expression, meaning that there exists an epigenetic blockade of learning and memory genes in the neurodegenerating brain. Very interestingly, she explained how transcriptome profiling in brain tissue of human AD patients shows significantly altered gene expression not only of neuronal genes but also of several immune response genes. Surprisingly, genetic predisposition is related to immune functions, whereas non-genetic factors affect neural pathways.
Manel Esteller (Cancer Epigenetics and Biology Program, PEBC-IDIBELL, Barcelona, Spain)
presented findings regarding the histone PTMs involved in cancer, and the potential epigenetic therapies targeting these marks. Histone modification profiles are altered in cancer, and it was recently observed that histone modifiers can also present genetic mutations. SETDB1 (SET domain bifurcated 1) methyltransferase is amplified in lung cancer tumors. Silencing of SETDB1 gene by shRNAs significantly decreases tumor growth. Mithramycin could be used to treat patients with SETDB1 amplification, because is able to inhibit the binding of a transcription factor to SETDB1 promoter. Another example is nuclear receptor binding SET domain protein 1 (NSD1), a histone methyltransferase, which is found methylated at the promoter in Soto's syndrome patients and in some tumors such as gliomas and neuroblastomas. The current goal is finding new drugs that target epigenetic alterations in cancer, taking into account that the effect of epigenetic drugs will depend on the tumor type and its genetic and epigenetic features. Some examples of targeting epigenetic alterations in cancer include the use of HDAC inhibitors for the treatment of cutaneous lymphoma, 3-Deazaneplanocin A (DZNep) as an enhancer of Kruppel-like factor 2 (KLF2) expression-a tumor suppressor protein silenced by the histone methyltransferase enhancer of Zeste 2 (EZH2) in cancer, and the CHR-6494 compound that was reported to be an inhibitor of the histone kinase Haspin.
Beyond Histone Acetylation
Shelley Berger (University of Pennsylvania, Philadelphia, USA) opened the session by reporting that p53 gain of function (GOF) mutants bind to epigenetic targets. p53 is mutated in more than 50% of human cancers. There are 6 "hot spot" mutations in p53 DNA binding domain that affect p53 function by altering the specificity of direct binding or altering its binding as a cofactor. p53 mutants do not bind correctly to the genome, and can bind to epigenetic targets, such as histone methyltransferase and acetyltransferase genes [mixed-lineage leukemia (MLL), monocytic leukemia zinc finger (MOZ)]. Knock down of p53 GOF mutants reduces histone methyl-transferase MLL expression and leads to a global reduction of H3K9me3 and H3K9Ac of the histone acetyltransferase MOZ. In general, p53 GOF mutants upregulate epigenetic pathways to activate oncogenic growth. Dr. Berger concluded her talk about unpublished data, remarking that p53 GOF mutant cells are "addicted" to epigenetic alterations.
Marian Martinez-Balbas (Molecular Biology Institute of Barcelona, Barcelona, Spain) reported on the involvement of histone methyl-transferase and demethylases in neural development. H3K27me3 increases during neurogenesis. Tri-methylation of H3K27 is catalyzed by EZH2 methyl-transferase, and JMJD3 (jumonji domain containing 3) demethylase is responsible for the removal of this mark. In addition, JMJD3 cooperates with SMAD family member 3 (SMAD3) to induce neural differentiation in neural stem cells (NSCs). This cooperation requires histone demethylase (HDM) activity. SMAD3 recruits JMJD3 to target promoters of transforming growth factor factor β (TGFβ), and JMJD3 is involved in TGFβ pathway by facilitating RNA Polymerase II elongation targeting promoters and binding enhancers in the genome-which finally results in the activation of genes in neural differentiation. Overall, Dr. Martinez-Balbas findings uncover the mechanism by which JMJD3 demethylase facilitates transcriptional activation.
Tamara Maes (Oryzon genomics, Barcelona, Spain) presented 2 new drugs in development by the company Oryzon Genomics, a biotech company whose objective is the identification of new biomarkers and their exploitation in diagnostic assays-or their use as drug targets. Lysine specific de-methylase1A (LSD1) is a H3K4me2/me1 demethylase, the overexpression of which is associated with bad prognoses in cancer. Oryzon developed ORY-1001, a potent selective inhibitor of LSD1 which is now in phase I of clinical trials for acute myeloid leukemia (AML). The catalytic domain of the LSD proteins is highly homologous to that of the monoamine oxidase A and B enzymes (MAOA and MAOB). Because of this, Go to:
Go to:
there are some MAO inhibitors such as tranylcypromine that can also inhibit LSD1. However, ORY-1001 has better pharmacological properties; they are testing ORY-2001, a dual orally available LSD1/MAOB inhibitor, for use in the treatment of neurological disorders. It is able to restore neural capacity in senescence-accelerated mouse prone-8 (SAMP8) mice, a model of senescence that presents many pathological alterations reminiscent of Alzheimer disease.
Olivier Cuvier (LBME/CNRS, Toulouse, France) discussed how long-range contacts in chromatin can be mapped with high precision from combined ChIP-Seq and Hi-C data, highlighting the role of insulator binding proteins (IBPs) and co-factors in long-range interactions and topological domains. IBPs further regulate chromatin locally through nucleosome dynamics by interacting with H3K36 histone methyltransferase nuclear receptor SET domain/Drosophila maternal effect sterile gene-4 (NSD/dMes-4) that favors the recruitment of HATs. NSD/dMes-4 and Set2 methylate H3K36me2/3 respectively, thereby triggering H3K36me3-dependent nucleosome positioning co-transcriptionally. IBPs/dMes-4 further regulates H3K27me3 deposition at hundreds of gene promoters, unveiling a model showing how such factors control nucleosome dynamics, gene expression, and H3K27me3 spreading.
David Landeira (University of Granada, Granada, Spain) reported a new role for jumonji AT-rich interactive domain 2 (Jarid2) in regulating planar cell pathways (PCP) required for embryonic stem cells (ESC) differentiation and early embryo development. Jarid2 is a component of the Polycomb Repressor Complex 2 (PCR2), which is involved in PCR2 recruitment and H3K27me3 deposition in ESCs, and plays an important role in ESC differentiation.
Jarid2-null ESCs express high levels of Nanog and low levels of non-canonical Wnt signaling components [wingless type 9a (Wnt9a), prickle homolog 1 (Prickle1), and frizzled class receptor 2 (Fzd2)]. Additionally, Jarid2 regulates a subset of planar cell polarity (PCP) genes, meaning that Jarid2 null cells are not able to differentiate properly or to self-organize in coherent colonies.
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